Discover
LXEO
Lexeo Therapeutics, Inc.
3.23
2 x 3.32
2 x 5.76
bid
ask
+
0.02
0.62%
2 @ 04:01 PM
3.23 +0.00 (0.00%)
| Ytd | -67.47% | |
| 1y | -60.61% |
3.12
day range
3.34
3.14
52 week range
10.63
| Open | 3.26 | Prev Close | 3.21 | Low | 3.12 | High | 3.34 | Mkt Cap | 265.14M |
| Vol | 961.38K | Avg Vol | 1.20M | EPS | -1.03 | P/E | N/A | Forward P/E | -2.24 |
| Beta | 1.63 | Short Ratio | 6.55 | Inst. Own | 91.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 4.33 | 200-d Avg | 5.75 | 1yr Est | 22.29 |
| Income Statement | |||
| Operating Expenses | 28.02M | ||
| Research and Development Expense | 19.03M | ||
| Selling, General and Administrative Expense | 8.99M | ||
| Operating Income | -28.02M | ||
| Interest Expense | 14.00K | ||
| Net Income | -25.87M | ||
| Net Income Common Stock | -25.87M | ||
| Net Income Common Stock (USD) | -25.87M | ||
| Consolidated Income | -25.87M | ||
| Earnings per Basic Share | -0.30 | ||
| Earnings per Basic Share (USD) | -0.30 | ||
| Earnings per Diluted Share | -0.30 | ||
| Earning Before Interest & Taxes (EBIT) | -25.85M | ||
| Earning Before Interest & Taxes (USD) | -25.85M | ||
| Weighted Average Shares | 85.63M | ||
| Weighted Average Shares Diluted | 85.63M | ||
| Balance Sheet | |||
| Cash and Equivalents | 96.08M | ||
| Cash and Equivalents (USD) | 96.08M | ||
| Investments | 144.73M | ||
| Investments Current | 118.87M | ||
| Investments Non-Current | 25.86M | ||
| Current Assets | 217.91M | ||
| Property, Plant & Equipment Net | 7.88M | ||
| Total Assets | 254.90M | ||
| Debt Current | 2.67M | ||
| Total Debt | 6.81M | ||
| Current Liabilities | 15.69M | ||
| Debt Non-Current | 4.14M | ||
| Total Liabilities | 19.84M | ||
| Accumulated Retained Earnings (Deficit) | -426.20M | ||
| Accumulated Other Comprehensive Income | -298.00K | ||
| Shareholders Equity | 235.06M | ||
| Shareholders Equity (USD) | 235.06M | ||
| Assets Non-Current | 36.99M | ||
| Total Debt (USD) | 6.81M | ||
| Liabilities Non-Current | 4.14M | ||
| Trade and Non-Trade Payables | 4.18M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 556.00K | ||
| Net Cash Flow from Financing | 24.40M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 21.07M | ||
| Capital Expenditure | -7.00K | ||
| Issuance (Purchase) of Equity Shares | 25.35M | ||
| Issuance (Repayment) of Debt Securities | -142.00K | ||
| Net Cash Flow from Investing | 14.26M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 14.27M | ||
| Net Cash Flow from Operations | -17.60M | ||
| Share Based Compensation | 5.69M | ||